公司名稱: 碧生源控股有限公司 呈交日期: 2026年1月2日 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00926 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 150,000,000 USD | | 0.0003333332 | USD | | 49,999.98 | | 增加 / 減少 (-) | | | 0 | | | USD | | 0 | | 本月底結存 | | | 150,000,000 USD | | 0.0003333332 | USD | | 49,999.98 | 本月底法定/註冊股本總額： ...

Market Overview - The Hong Kong stock market experienced fluctuations and adjustments, with the Hang Seng Index down 0.92% to 25,737.85 points, the Hang Seng Tech Index down 1.79% to 5,537.11 points, the National Enterprises Index down 1.2% to 8,970.29 points, and the Red Chip Index down 0.3% to 4,137.97 points due to the significant drop in US stocks last Friday [1] - Major technology stocks saw declines, with Alibaba down 2.73%, Tencent Holdings down 1.54%, JD Group down 1.12%, Xiaomi down 2.28%, NetEase down 0.18%, Meituan down 1.07%, Kuaishou down 3.85%, and Bilibili down 1.12% [1] - Insurance stocks performed well, with China Ping An reaching a four-year high, while the biopharmaceutical sector weakened, with Baijiazhensheng down over 6% [1] - Semiconductor stocks faced significant declines, with Huahong Semiconductor down over 6% [1] Company News - China Merchants Energy (01138.HK) signed shipbuilding contracts with Dalian China Merchants Heavy Industry, Yangzhou China Merchants Heavy Industry, and Guangdong China Merchants Heavy Industry for the construction of one ethylene ship and eighteen oil tankers, with a total cost of RMB 7.882 billion [2] - ZhongAn Online (06060.HK) reported a cumulative original insurance premium income of approximately RMB 32.904 billion for the first eleven months [3] - R&F Properties (02777.HK) achieved total sales revenue of approximately RMB 12.7 billion in the first eleven months, representing a year-on-year increase of 24.63% [4] - Yida China (03639.HK) reported a contract sales amount of approximately RMB 681 million for the first eleven months, a year-on-year decrease of 23.22% [5] - Kason International (00496.HK) signed a steel structure procurement contract with suppliers, involving an investment of RMB 43.5366 million [5] Clinical and Regulatory Updates - Boke Vision Cloud-B (02592.HK) successfully held a meeting after the second phase of clinical trials for CBT-004 [6] - Fuhong Hanlin (02696.HK) received acceptance from the National Medical Products Administration for the listing registration application of Hanshuo® in combination with chemotherapy for neoadjuvant/adjuvant treatment of gastric cancer, which has been included in priority review [6] - Shijiazhuang Pharmaceutical Group (01093.HK) received approval for a new indication for Donyi® (liposomal irinotecan injection) for first-line treatment in patients with metastatic pancreatic cancer [6] - Hengrui Medicine (01276) received a clinical trial approval notice for HRS-1780 tablets [8] Investment Insights - Guosen Securities indicated that the short-term adjustment in the Hong Kong stock market opens up space for a market rise in 2026, with net inflows from southbound funds exceeding RMB 110 billion in November [13] - Dongwu Securities highlighted that the main focus for Hong Kong stocks is on technology and cyclical sectors, while also paying attention to innovative drugs, suggesting a barbell allocation strategy due to potential macro and political risks [13] - CITIC Securities projected that the Hong Kong stock market will benefit from internal "14th Five-Year Plan" catalysts and external fiscal and monetary easing from major economies, expecting a sustainable upward trend in revenue and profit [13] - Dongwu Securities also forecasted a continued recovery in the Hong Kong stock market in 2026, citing expected interest rate cuts by the Federal Reserve and a temporary easing of Sino-US relations [14]

Market Overview - The Hong Kong stock market opened lower on December 15, with the Hang Seng Index down 1% at 25,718.14 points, the Hang Seng Tech Index down 1.34% at 5,562.67 points, and the State-Owned Enterprises Index down 1.09% at 8,980.13 points [1] - Major tech stocks declined, including Alibaba down 2.14%, Tencent down 1.62%, and JD.com down 0.61% [1] - The innovative drug sector saw several stocks open lower, with Genscript Biotech down 5.92% and Zai Lab down 3.48% [1] - Chinese brokerage stocks collectively fell, with Everbright Securities dropping over 1% [1] - The automotive sector also experienced declines, with Li Auto down over 2% and XPeng down nearly 2% [1] - However, three-child policy concept stocks and photovoltaic stocks mostly rose, with star stock Jinxin Fertility rising about 3% [1] Company News - China Merchants Energy (01138.HK) signed shipbuilding contracts for one ethylene ship and eighteen oil tankers, totaling RMB 7.882 billion [2] - ZhongAn Online (06060.HK) reported cumulative original insurance premium income of approximately RMB 32.904 billion for the first eleven months [3] - R&F Properties (02777.HK) achieved total sales revenue of approximately RMB 12.7 billion in the first eleven months, a year-on-year increase of 24.63% [4] - Yida China (03639.HK) reported contract sales amounting to approximately RMB 681 million in the first eleven months, a year-on-year decrease of 23.22% [5] - Bole Technology (02592.HK) successfully held a meeting after the second phase of clinical trials for CBT-004 [6] - Junshi Biosciences (02696.HK) received acceptance for its marketing application for Hansizhuang® in combination with chemotherapy for gastric cancer [6] - CSPC Pharmaceutical Group (01093.HK) received approval for a new indication for its drug, Donyin® (liposomal irinotecan injection), for first-line treatment in metastatic pancreatic cancer patients [6] - Biyuan (00926.HK) increased its investment in ERX to maintain a 3% stake to support innovative research and development of non-GLP-1 weight loss therapies [7] - Hengrui Medicine (01276) received approval for clinical trials for HRS-1780 tablets [8] - AVIC Industry (02357.HK) plans to acquire a 59.1816% partnership interest in Hangtou Yuhua for a consideration of RMB 202 million [9] - China Environmental Resources (01130.HK) intends to acquire 90% equity in Sichuan Yuanlai Shun Recycling Resources Co., Ltd. for RMB 9 million [10] - AVIC Industry (02357.HK) proposed to implement full circulation of H-shares [11] - Yabo Technology Holdings (08279.HK) signed a framework agreement with Alipay (Hangzhou) [12] Institutional Insights - Guosen Securities indicated that the short-term adjustment in the Hong Kong stock market opens up space for a market rise in 2026, with net inflows from southbound funds exceeding RMB 110 billion in November [13] - CITIC Securities noted strong performance in gold and silver, while other risk assets were weak, predicting a segmented market for precious metals in 2025 [13] - CITIC Securities also emphasized the importance of resource self-sufficiency in the lithium industry, highlighting the need for low-cost quality resources to navigate market cycles [14]

Core Viewpoint - The company anticipates a significant fair value loss of approximately RMB 16.3 million related to its investment in ERX Pharmaceuticals Inc. due to recent shifts in the U.S. capital market, which have favored AI and tech sectors over traditional drug development [1][2] Group 1: Fair Value Loss and Market Conditions - The fair value loss is primarily attributed to a decline in financing activities for traditional drug development and clinical research, impacting ERX's new drug development due to a lack of external funding [1] - The board believes that this fair value loss will not have a significant adverse effect on the company's existing business, operations, or financial condition, as the group's liquidity remains strong and overall financial health is stable [1] Group 2: Investment in ERX Pharmaceuticals - ERX focuses on innovative drug discovery and clinical development for obesity and related metabolic diseases, which aligns synergistically with the company's core business segments [1] - ERX has recently proposed a capital increase of $6 million to strengthen its financial position and support ongoing operations, and the board has resolved to participate in this capital increase to maintain its approximately 3% stake in ERX [1][2] Group 3: Strategic Importance of Further Investment - The board believes that further investment will prevent dilution and protect the book value of the company's investment, especially given ERX's leading non-GLP-1 therapy for patients who do not respond well to semaglutide [2] - ERX's drug for Prader-Willi syndrome has received orphan drug designation and fast track designation from the FDA, reinforcing the board's confidence in the long-term development of ERX [2] - Maintaining the stake in ERX is seen as crucial for preserving strategic partnerships in core business areas, ensuring consistency in technology, supply chain, and market opportunities, which will benefit the company's strategic development and long-term growth [2]

Company News - China COSCO Shipping Energy Transportation Co., Ltd. (中远海能) has signed shipbuilding contracts with Dalian COSCO Shipping Heavy Industry, Yangzhou COSCO Shipping Heavy Industry, and Guangdong COSCO Shipping Heavy Industry for the construction of one ethylene ship and eighteen oil tankers, with a total cost of RMB 7.882 billion [1] - ZhongAn Online P&C Insurance Co., Ltd. (众安在线) reported a total original insurance premium income of approximately RMB 32.904 billion for the first eleven months [2] - R&F Properties Co., Ltd. (富力地产) achieved total sales revenue of approximately RMB 12.7 billion in the first eleven months, representing a year-on-year increase of 24.63% [3] - Yida China Holdings Limited (亿达中国) reported a contracted sales amount of approximately RMB 681 million for the first eleven months, a year-on-year decrease of 23.22% [4] - Karsen International Holdings Limited (卡森国际) has entered into a steel structure procurement contract with suppliers, involving an investment of RMB 43.5366 million [4] Clinical and Regulatory Updates - Bolex Cloud-B (拨康视云-B) successfully held a meeting after the second phase of clinical trials for CBT-004 [5] - Innovent Biologics, Inc. (复宏汉霖) has had its application for the marketing registration of Hansizhuang® combined chemotherapy for gastric cancer accepted by the National Medical Products Administration, and it has been included in the priority review [5] - CSPC Pharmaceutical Group Limited (石药集团) received approval for a new indication for Donyi® (Irinotecan Liposome Injection) for first-line treatment in patients with metastatic pancreatic cancer [5] - Heng Rui Medicine (恒瑞医药) received a clinical trial approval notice for HRS-1780 tablets [7] Investment and Acquisition Activities - AVIC Aviation Industry Corporation (中航科工) plans to acquire a 59.1816% partnership interest in Hangtou Yuhua for a consideration of RMB 202 million [8] - China Environment Resources Holdings Limited (中国环境资源) intends to acquire 90% equity in Sichuan Yuanlai Shun Recycling Resources Co., Ltd. for RMB 9 million [9] - AVIC Aviation Industry Corporation (中航科工) has proposed to implement full circulation of H-shares [10] - Yabo Technology Holdings Limited (亚博科技控股) has entered into a framework agreement with Alipay (Hangzhou) [11] Financing and Buyback Activities - Yum China Holdings, Inc. (百胜中国) has entered into a share buyback agreement with a total repurchase amount of approximately USD 460 million, including about HKD 880 million under the Hong Kong plan, as part of a plan to return USD 1.5 billion to shareholders through dividends and share buybacks by 2026 [12] - Tencent Holdings Limited (腾讯控股) repurchased approximately 1.044 million shares for about HKD 636 million, with repurchase prices ranging from HKD 601.5 to HKD 616 [13] - Xuanwu Cloud (玄武云) repurchased 6,000 shares for a total of HKD 6,467.79, with prices between HKD 1.05 and HKD 1.07 [14] - China COSCO Shipping Holdings Co., Ltd. (中远海控) repurchased approximately 4.461 million shares for about HKD 60.8605 million, with prices ranging from HKD 13.38 to HKD 13.82 [15] - Geely Automobile Holdings Limited (吉利汽车) repurchased approximately 1.362 million shares for about HKD 23.9241 million, with prices between HKD 17.29 and HKD 17.82 [16] - China Anshun Energy (中国安储能源) plans to issue a total of 524 million shares at a discount of approximately 19.12%, aiming to raise about HKD 288.2 million [16]

相关事件 碧生源(00926.HK)：预计因投资ERX录得公允值亏损约1630万元 碧生源(00926.HK)2025年上半年收入 2.59亿元 同比上升1.8% 格隆汇12月12日丨碧生源(00926.HK)发布公告，根据初步评估，公司预期将就其对ERX Pharmaceuticals Inc.("ERX"，一家根据特拉华州法律注册成立的临床阶段生物医药公司)的投资录得重大公允值亏损约 人民币1630万元。该公允值亏损的产生主要是由于美国资本市场环境近期出现转变，投资者资金明显倾 向人工智能(AI)等科技板块，导致传统药物开发及临床研究的融资活动低迷，令ERX新药开发活动缺乏 外部资金。此融资困难对ERX的短期估值造成压力，导致ERX的估值大幅下降。 董事会认为公允值亏损将不会对公司现有业务、运营或财务状况造成任何重大不利影响。集团的流动资 金维持强劲，其整体财务及运营状况亦维持稳健。 ...

Core Viewpoint - The company anticipates a significant fair value loss of approximately RMB 16.3 million related to its investment in ERX Pharmaceuticals Inc. due to a shift in the U.S. capital market environment, which has led to a decline in funding for traditional drug development and clinical research [1][2] Group 1 - The fair value loss is primarily attributed to a lack of external funding for ERX's new drug development activities, resulting in downward pressure on ERX's short-term valuation [1] - The board believes that the fair value loss will not have a significant adverse impact on the company's existing business, operations, or financial condition, as the group's liquidity remains strong and overall financial and operational status is stable [1] - ERX focuses on the discovery and clinical development of innovative drugs for obesity and obesity-related metabolic diseases, which aligns synergistically with the company's core business segments [1] Group 2 - ERX has recently proposed a capital increase of $6 million to strengthen its financial position and provide funding for ongoing business operations [1] - The board has resolved to participate in this capital increase to maintain its approximately 3% stake in ERX, aiming to prevent further dilution of its investment value [1][2] - The board believes that further investment aligns with the overall interests of the company and its shareholders, as it can avoid immediate erosion of the investment's book value and supports ERX's long-term development [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何 部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 BESUNYEN HOLDINGS COMPANY LIMITED 碧生源控股有限公司 （於開曼群島註冊成立的有限公司） （股份代號：926） 內幕消息 本公告由碧生源控股有限公司（「本公司」，連同其附屬公司為「本集團」）根據香港聯 合交易所有限公司證券上市規則（「上市規則」）第13.09(2)(a)條及香港法例第571章 證券及期貨條例第XIVA部的內幕消息條文（定義見上市規則）刊發。 – 2 – 本公司董事會（「董事會」）謹此知會本公司股東（「股東」）及潛在投資者，根據初步評 估，本公司預期將就其對ERX Pharmaceuticals Inc.（「ERX」，一家根據特拉華州法 律註冊成立的臨床階段生物醫藥公司）的投資（「投資」）錄得重大公允值虧損約人民 幣16.3百萬元。該公允值虧損的產生主要是由於美國資本市場環境近期出現轉變， 投資者資金明顯傾向人工智能(AI)等科技板塊，導致傳統藥物開發及臨床 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 公司名稱: 碧生源控股有限公司 呈交日期: 2025年12月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00926 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 150,000,000 USD | | 0.0003333332 | USD | | 49,999.98 | | 增加 / 減少 (-) | | | 0 | | | USD | | 0 | | 本月底結存 | | | 150,000,000 USD | | 0.0003333332 | USD | | 49,999.98 | 本月底法定/註冊股本總額： USD 49,999.98 ...

Group 1: Company Performance - Zijin Mining (02899.HK) reported a net profit of 4.653 billion yuan for Q3 2021, representing a year-on-year increase of 116.34% [1] - Zijin Mining's total revenue for the first three quarters of 2021 reached 168.976 billion yuan, up 29.55% year-on-year [1] - Shenzhen Expressway (00548.HK) expects a net profit of approximately 1.86 billion yuan for the first three quarters, a year-on-year increase of about 195% [4] - Haohai Biological Technology (06826.HK) anticipates a net profit increase of 166.32% to 192.95% for the first three quarters, estimating between 300 million to 330 million yuan [5] Group 2: Insurance and Premiums - China Life (02628.HK) reported original insurance premium income of approximately 553.4 billion yuan for the first three quarters, a year-on-year growth of 1.8% [3] - Zhong An Online (06060.HK) achieved premium income of 15.802 billion yuan for the first three quarters, reflecting a year-on-year increase of 41.75% [8] Group 3: Market Activity and Corporate Actions - Jingxi International (02788.HK) announced a privatization proposal at a premium of approximately 54.4% over the closing price on October 6, 2021 [2] - The company plans to cancel and remove shares, compensating shareholders at a cancellation price of 0.88 HKD per share [2]